Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Post by biorunon Nov 23, 2022 5:04pm
221 Views
Post# 35123371

Looks like up from here

Looks like up from hereGood news recently but great news today. Some may not like Wanbang but in the end the two ends of this legacy arrangement picked themselves up, have a war chest of scientific data, know how to produce the pills, and now focussed on something more relevant towards moving another (or two) deal forward. 

If that deal happens, that will be 3 major biopharmas working with Sirona. The 4th? - that is the human indication they refer to, and maybe next year a 5th and 6th on anti-aging and anti-viral.

Its all up from here in my personal opinion. 11.5 cents in hindsight now looks like the steal of the century, and maybe also big baby's buy at 16 cents will turn green as well.

GLTA.
<< Previous
Bullboard Posts
Next >>